Compare Stocks: INAB, TIL, ELTX, and TVGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$1.93 +6.3%	$2.60	$1.71 ▼ $16.00	$50.85M	1.29	690,794 shs	248,064 shs
INAB IN8bio	$1.41 +5.6%	$1.11	$0.88 ▼ $2.73	$13.85M	0.3	64,170 shs	66,406 shs
TIL Instil Bio	$7.24 -0.1%	$7.37	$5.67 ▼ $21.98	$49.05M	1.91	50,701 shs	4,612 shs
TVGN Tevogen Bio	$6.72 +1.5%	$6.85	$3.64 ▼ $39.83	$43.75M	0.17	22,301 shs	6,370 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	-1.09%	-2.67%	-32.59%	-43.48%	-83.21%
INAB IN8bio	+5.02%	+23.64%	+23.64%	-4.23%	-37.33%
TIL Instil Bio	+1.40%	0.00%	-4.86%	-6.34%	-59.46%
TVGN Tevogen Bio	-1.93%	-14.70%	-5.16%	+14.73%	-83.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$1.93 +6.3%	$2.60	$1.71 ▼ $16.00	$50.85M	1.29	690,794 shs	248,064 shs
INAB IN8bio	$1.41 +5.6%	$1.11	$0.88 ▼ $2.73	$13.85M	0.3	64,170 shs	66,406 shs
TIL Instil Bio	$7.24 -0.1%	$7.37	$5.67 ▼ $21.98	$49.05M	1.91	50,701 shs	4,612 shs
TVGN Tevogen Bio	$6.72 +1.5%	$6.85	$3.64 ▼ $39.83	$43.75M	0.17	22,301 shs	6,370 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	-1.09%	-2.67%	-32.59%	-43.48%	-83.21%
INAB IN8bio	+5.02%	+23.64%	+23.64%	-4.23%	-37.33%
TIL Instil Bio	+1.40%	0.00%	-4.86%	-6.34%	-59.46%
TVGN Tevogen Bio	-1.93%	-14.70%	-5.16%	+14.73%	-83.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELTX Elicio Therapeutics	2.50	Moderate Buy	$15.00	691.56% Upside
INAB IN8bio	2.00	Hold	$4.00	175.86% Upside
TIL Instil Bio	1.67	Reduce	$7.00	-3.31% Downside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,374.93% Upside

Current Analyst Ratings Breakdown

Latest INAB, TIL, ELTX, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ELTX Elicio Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
9/2/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	INAB IN8bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/14/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.09 per share	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	$2.82 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
INAB IN8bio	-$19.44M	-$1.62	N/A	N/A	N/A	N/A	-91.18%	-76.93%	11/5/2026 (Estimated)
TIL Instil Bio	-$71.37M	-$4.47	N/A	N/A	N/A	N/A	-26.78%	-14.89%	11/16/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest INAB, TIL, ELTX, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
8/6/2026	Q2 2026	INAB IN8bio	-$0.3437	-$0.25	+$0.0937	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELTX Elicio Therapeutics	1.20	2.77	2.77
INAB IN8bio	N/A	8.21	8.21
TIL Instil Bio	0.79	21.67	21.67
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELTX Elicio Therapeutics	35.03%
INAB IN8bio	92.05%
TIL Instil Bio	60.56%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ELTX Elicio Therapeutics	50.90%
INAB IN8bio	14.50%
TIL Instil Bio	47.00%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELTX Elicio Therapeutics	N/A	26.28 million	12.90 million	Not Optionable
INAB IN8bio	18	9.86 million	8.43 million	Not Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data
TVGN Tevogen Bio	3	6.51 million	2.24 million	N/A

INAB, TIL, ELTX, and TVGN Headlines

Recent News About These Companies

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

September 30 at 4:30 PM | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% - Time to Buy?

September 23, 2026 | americanbankingnews.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INAB, TIL, ELTX, and TVGN Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

$1.93 +0.11 (+6.26%)

As of 03:56 PM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

IN8bio NASDAQ:INAB

$1.40 +0.08 (+5.64%)

As of 03:56 PM Eastern

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Instil Bio NASDAQ:TIL

$7.24 -0.01 (-0.07%)

As of 03:56 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tevogen Bio NASDAQ:TVGN

$6.72 +0.10 (+1.51%)

As of 03:55 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INAB, TIL, ELTX, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INAB, TIL, ELTX, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INAB, TIL, ELTX, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INAB, TIL, ELTX, and TVGN Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

IN8bio NASDAQ:INAB

Instil Bio NASDAQ:TIL

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INAB, TIL, ELTX, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INAB, TIL, ELTX, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INAB, TIL, ELTX, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INAB, TIL, ELTX, and TVGN Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

IN8bio NASDAQ:INAB

Instil Bio NASDAQ:TIL

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools